Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.

Miller CH, Rice AS, Boylan B, Shapiro AD, Lentz SR, Wicklund BM, Kelly FM, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2013 Jul;11(7):1300-9. doi: 10.1111/jth.12259.

2.

Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance.

Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2012 Jun;10(6):1055-61. doi: 10.1111/j.1538-7836.2012.04705.x.

3.

Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.

Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators.

J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11.

4.

Characteristics of hemophilia patients with factor VIII inhibitors detected by prospective screening.

Miller CH, Rice AS, Boylan B, Payne AB, Kelly FM, Escobar MA, Gill J, Leissinger C, Soucie JM; Hemophilia Inhibitor Research Study Investigators.

Am J Hematol. 2015 Oct;90(10):871-6. doi: 10.1002/ajh.24104. Epub 2015 Sep 10.

PMID:
26147783
5.

[Comparison of modified Bethesda assay and Nijmegen assay in detecting FVII inhibitor in patients with hemophilia A].

Fan LK, Wang ZW, Hua BL, Su W, Wang SJ, Zhao YQ.

Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2009 Oct;31(5):551-4. Chinese.

6.

Antibodies to factor VIII in plasma of patients with hemophilia A and normal subjects.

Batlle J, Gómez E, Rendal E, Torea J, Lourés E, Couselo M, Vila P, Sedano C, Tusell X, Magallón M, Quintana M, González-Boullosa R, López-Fernández MF.

Ann Hematol. 1996 May;72(5):321-6.

PMID:
8645745
7.

Alloantibodies to factor VIII in haemophilia.

Zakarija A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, Butenas S, Mann KG, Green D.

Haemophilia. 2011 Jul;17(4):636-40. doi: 10.1111/j.1365-2516.2010.02468.x. Epub 2011 Feb 7.

PMID:
21299745
8.

Validation of 4% albumin as a diluent in the Bethesda Assay for FVIII inhibitors.

Kershaw GW, Chen LS, Jayakodi D, Dunkley SM.

Thromb Res. 2013;132(6):735-41. doi: 10.1016/j.thromres.2013.09.018. Epub 2013 Sep 21.

PMID:
24119613
9.

[Modified Bethesda, modified Nijmegen and blank assays for coagulation factor VIII inhibitor detection and factors affecting the results].

Feng HM, Li Q, Xu WS, Chen DM, Zheng L.

Nan Fang Yi Ke Da Xue Xue Bao. 2016 Apr;36(4):592-5. Chinese.

PMID:
27113194
10.

Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity.

Towfighi F, Gharagozlou S, Sharifian RA, Kazemnejad A, Esmailzadeh K, Managhchi MR, Shokri F.

Acta Haematol. 2005;114(2):84-90.

PMID:
16103630
11.

Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.

Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Bergés-García A, Rodríguez-Zepeda MD, Pompa-Garza MT, Jaloma-Cruz AR.

Haemophilia. 2014 Jan;20(1):e7-14. doi: 10.1111/hae.12309.

PMID:
24354488
12.

Nijmegen-Bethesda assay to measure factor VIII inhibitors.

Duncan E, Collecutt M, Street A.

Methods Mol Biol. 2013;992:321-33. doi: 10.1007/978-1-62703-339-8_24.

PMID:
23546724
13.

Frequency of specific coagulation inhibitors and antiphospholipid antibodies in Tunisian haemophiliacs.

Kraiem I, Hadhri S, El Omri H, Sassi R, Chaabani W, Ennabli S, Skouri H.

Ann Biol Clin (Paris). 2012 Nov-Dec;70(6):659-65. doi: 10.1684/abc.2012.0765.

PMID:
23207810
14.

Expanding the ortholog approach for hemophilia treatment complicated by factor VIII inhibitors.

Zakas PM, Vanijcharoenkarn K, Markovitz RC, Meeks SL, Doering CB.

J Thromb Haemost. 2015 Jan;13(1):72-81. doi: 10.1111/jth.12755. Epub 2014 Nov 11.

15.

Effects of recombinant human prothrombin on thrombin generation in plasma from patients with hemophilia A and B.

Hansson KM, Gustafsson D, Skärby T, Frison L, Berntorp E.

J Thromb Haemost. 2015 Jul;13(7):1293-300. doi: 10.1111/jth.12997. Epub 2015 Jun 8.

PMID:
25944555
16.

[Diagnosis and influence factor of antibody to coagulation factors in hemophilia].

Zhao XA, Liu SX, Li F, Liu YG, Ren YP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2011 Aug;19(4):971-4. Chinese.

PMID:
21867626
17.
18.

Clinical evaluation of recombinant factor VIII preparation (Kogenate) in previously treated patients with hemophilia A: descriptive meta-analysis of post-marketing study data.

Yoshioka A, Fukutake K, Takamatsu J, Shirahata A; Kogenate Post-Marketing Surveillance Study Group.

Int J Hematol. 2006 Aug;84(2):158-65.

PMID:
16926139
19.

Antibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.

Klintman J, Hillarp A, Donfield S, Berntorp E, Astermark J.

Haemophilia. 2013 Jan;19(1):106-12. doi: 10.1111/j.1365-2516.2012.02903.x. Epub 2012 Jul 5.

PMID:
22762454
20.

Anti-A2 and anti-A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A.

Lapalud P, Rothschild C, Mathieu-Dupas E, Balicchi J, Gruel Y, Laune D, Molina F, Schved JF, Granier C, Lavigne-Lissalde G.

J Thromb Haemost. 2015 Apr;13(4):540-7. doi: 10.1111/jth.12846. Epub 2015 Feb 27.

PMID:
25603934
Items per page

Supplemental Content

Write to the Help Desk